1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,017 | 0,026 | 23.12. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16.12. | Genflow Biosciences PLC: Genflow Completes Dosing Phase of Canine Gene Therapy Trial | 201 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| 16.12. | Genflow Biosciences - Completion of Dosing Phase of Canine Gene Therapy | 1 | RNS | ||
| 11.12. | Genflow Biosciences to attend J.P. Morgan Healthcare Conference | 2 | Investing.com | ||
| 11.12. | Genflow Biosciences nimmt an J.P. Morgan Healthcare Conference teil | 4 | Investing.com Deutsch | ||
| 11.12. | Genflow Biosciences PLC: Genflow to Attend Healthcare Conference | 206 | ACCESS Newswire | Genflow to Attend the 44th Annual J.P. Morgan Healthcare Conference LONDON, UK / ACCESS Newswire / December 11, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company"), a... ► Artikel lesen | |
| 11.12. | Genflow Biosciences - Genflow to Attend Healthcare Conference | 2 | RNS | ||
| 31.10. | Genflow Biosciences PLC Announces Total Voting Rights | 234 | ACCESS Newswire | LONDON, UK / ACCESS Newswire / October 31, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company"), an emerging leader in the field of longevity research, focused on developing... ► Artikel lesen | |
| GENFLOW BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 31.10. | Genflow Biosciences - Total Voting Rights | 2 | RNS | ||
| 24.10. | Genflow Biosciences PLC Announces Holding(s) in Company | 213 | ACCESS Newswire | LONDON, UK / ACCESS Newswire / October 24, 2025 / TR-1: Standard form for notification of major holdings1. Issuer DetailsISINGB00BP2C3V08Issuer NameGENFLOW BIOSCIENCES PLCUK or Non-UK IssuerUK2. Reason... ► Artikel lesen | |
| 22.10. | TRADING UPDATES: Genflow patent progress; Accsys new debt facilities | 2 | Alliance News | ||
| 22.10. | Genflow Biosciences announces second European patent application | 2 | Seeking Alpha | ||
| 22.10. | Genflow Biosciences PLC Announces Second European Patent Application | 253 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| 22.10. | Genflow Biosciences - Second European Patent Application | 2 | RNS | ||
| 20.10. | Genflow Biosciences says European patent publication is "step forward" | 2 | Alliance News | ||
| 20.10. | Genflow Biosciences PLC Announces Recognition of Patentability of Claims | 196 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| 20.10. | Genflow Biosciences - Recognition of Patentability of Claims | 2 | RNS | ||
| 10.10. | Genflow Biosciences hails data from trial of dog ageing gene therapy | 1 | Alliance News | ||
| 10.10. | Genflow Biosciences PLC Announces Update on Animal Health Program | 259 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| 10.10. | Genflow Biosciences - Update on Animal Health Program | 1 | RNS | ||
| 09.10. | Genflow Biosciences PLC Announces Update, Equity Issue and PDMR Notification | 241 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen |
1 2 3 4 Weiter >>
63 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AMGEN | 332,93 | -0,31 % | Amneal Pharma, MAbxience: FDA Approves Denosumab Biosimilars Referencing Amgen's Prolia And XGEVA | THOUSAND OAKS (dpa-AFX) - Amneal Pharmaceuticals, Inc. (AMRX) announced late Monday that the U.S. Food and Drug Administration has approved the Biologics Licensing Applications or BLAs for Boncresa... ► Artikel lesen | |
| INSMED | 177,88 | +0,26 % | INSMED INC kurz vor dem Durchbruch - ich greife jetzt zu! | ||
| ROIVANT SCIENCES | 22,230 | -1,20 % | Roivant Sciences: Roivant Highlights Continued Pipeline Progress and Outlook for Company's Next Phase of Growth at 2025 Investor Day | Roivant enters new phase of corporate journey with 3+ launches, 4+ NDA/BLA filings, 8+ pivotal and 3+ proof-of-concept study readouts expected over the next three yearsHighlighting clinical execution... ► Artikel lesen | |
| MODERNA | 31,200 | -4,73 % | Nvidia Rises, Moderna and Brown-Forman Slump, and More | ||
| CYTOKINETICS | 63,11 | -1,67 % | FDA Approval Puts New Cytokinetics Heart Drug in Competition With Fast-Growing BMS Med | ||
| ARCUTIS BIOTHERAPEUTICS | 28,970 | -1,63 % | Arcutis Biotherapeutics, Inc.: FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5 | Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children... ► Artikel lesen | |
| EXELIXIS | 46,240 | -0,58 % | Adagene Inc.: Adagene Expands SAFEbody Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate | SAN DIEGO and SUZHOU, China, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (Nasdaq: ADAG) today announced an amendment to the 2021 collaboration and license agreement with Exelixis.... ► Artikel lesen | |
| NEUROCRINE BIOSCIENCES | 145,26 | -1,14 % | Neurocrine: Phase 3 Study Of Valbenazine In Dyskinetic Cerebral Palsy Fails To Meet Main Goal | WASHINGTON (dpa-AFX) - Neurocrine Biosciences Inc. (NBIX) announced that its Phase 3 KINECT-DCP study evaluating valbenazine in pediatric and adult participants with dyskinetic cerebral palsy... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 784,48 | +0,10 % | Regeneron Pharmaceuticals: Nach erfolgreichem Ausbruch - Pullback-Szenario bietet attraktives Setup! | Chance nach charttechnischem Befreiungsschlag! Rückblick Seit Ende Oktober befindet sich die Regeneron-Aktie in einem stabilen Aufwärtstrend. Nach einem scharfen Rücksetzer hat sich der Kurs über der... ► Artikel lesen | |
| GUARDANT HEALTH | 102,98 | +0,59 % | Guardant Health is the top performing healthcare services stock YTD | ||
| PTC THERAPEUTICS | 78,56 | +0,24 % | PTC Therapeutics erhält Zulassung für PKU-Medikament Sephience in Japan | ||
| PROTAGONIST THERAPEUTICS | 88,78 | -0,07 % | Protagonist Therapeutics: Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice | NEW YORK, NY / ACCESS Newswire / November 27, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) (the "Company") today announced that it has received a notification letter from the Nasdaq Listing Qualifications... ► Artikel lesen | |
| CIDARA THERAPEUTICS | 220,80 | -0,03 % | ROUNDUP/Aktien New York Schluss: Nasdaq holt Kursrutsch auf - Dow im Minus | NEW YORK (dpa-AFX) - Nach den zurückliegenden Kursausschlägen haben die Anleger ihre Nervosität am Freitag nicht abgelegt. Der Handel ging mit tiefen Verlusten los, weil neben der Bewertung von Technologiekonzernen... ► Artikel lesen | |
| DYNAVAX | 15,380 | 0,00 % | Sanofi will US-Impfstoffhersteller Dynavax für 2,2 Milliarden Dollar kaufen | PARIS (dpa-AFX) - Der Pharmakonzern Sanofi will den US-Impfstoffhersteller Dynavax für gut zwei Milliarden Dollar kaufen. Das Gebot liege bei 15,50 US-Dollar je Aktie in bar, teilten die Franzosen... ► Artikel lesen | |
| AMICUS THERAPEUTICS | 14,250 | 0,00 % | XFRA AM6: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen |
GENFLOW BIOSCIENCES PLC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,008 (-27,78 %) liegt der Kurs bei 0,020 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GENFLOW BIOSCIENCES PLC finden Sie auf Wallstreet Online.